The group’s principle activity is to develop therapeutics targeting protein kinase C for treatment of ischemic diseases, pain, cancer, diabetes and inflammation. The group’s programs include protein kinase C Inhibition, protein kinase C Activation, and protein kinase C Inhibition. The group operates from United States.
Executive Information
Name
Title
Email
Steven James
CEO, Pres.
N/A
Gregory Bell
VP - Clinical Research, Development, Chief Medical Officer
